


## Advancing Cancer Diagnosis

### CORPORATE PROFILE

OncoCyte is focused on the discovery, development, and commercialization of innovative, **liquid biopsy tests** that improve diagnosis and reduce healthcare costs for some of the most common and deadly cancers.

While current tissue biopsies use invasive procedures to determine if a tumor is benign or malignant, our highly-accurate tests offer a new, non-invasive alternative that helps clinicians make decisions and potentially avoid risky and costly downstream procedures for their patients.




\*Potentially malignant, clinician to determine follow up procedure.

### STRATEGIC PROFILE

- Developing non-invasive tests to address significant unmet need in the field of cancer diagnostics
- First product launch, confirmatory lung cancer test, planned for second-half 2017
- Breast cancer confirmatory test being developed as second commercial product
- Product pipeline focused on tests for the most common and deadly cancers
- Experienced leadership team with deep R&D and commercialization experience

### Pipeline



### STOCK INFO

(as of March 31, 2017)


NYSE MKT: OCX

Stock Price: \$5.95

Market Cap: \$175

# ONCOCYTE'S PIPELINE PRODUCTS

**Lung Cancer:** Twelve to 15 million Americans have lung nodules. While the vast majority of these nodules are benign the current standard-of-care for diagnosis of nodules is to perform an invasive, often risky and expensive, tissue biopsy. Unlike other types of biopsies, lung biopsies can result in significant complications and, in some cases, death. OncoCyte's lead product is a blood test intended to distinguish benign from suspicious nodules to potentially avoid unnecessary biopsies.



**Pipeline:** OncoCyte's pipeline products are being developed leveraging proprietary algorithms in conjunction with sets of molecular markers that are differentially expressed in specific types of cancer. OncoCyte's focus on the most common and deadly cancers combined with its experienced leadership team enable it to capitalize on significant commercial opportunities while improving patient outcomes.

## COMPANY LEADERSHIP

**William Annett**  
President & Chief Executive Officer

**Russell Skibsted**  
Chief Financial Officer

**Lyssa Friedman**  
VP, Clinical and Regulatory Affairs

**William Haack**  
VP, Market Access & Business Operations

**Lyndal Hesterberg, PhD**  
SVP, Research & Development

**Kristine C. Mechem, PhD**  
VP, Marketing & Planning

**William Seltzer, PhD, FACMG**  
VP, Clinical Services

## ANALYST COVERAGE

**Benchmark**  
Raymond Myers, CFA

**Chardan Capital Markets**  
Keya Nakae, CFA

**Janney Capital Markets**  
Paul Knight, CFA

**Lake Street Capital Markets**  
Bruce D. Jackson

## INVESTOR CONTACT

**EVG Group, Inc.**  
Michael Polyviou or Doug Sherk  
mpolyviou@evcgroup.com  
dsherk@evcgroup.com



**OncoCyte Corporation**  
1010 Atlantic Avenue, Suite 102, Alameda, CA 94501  
www.oncoyte.com • info@oncoyte.com